US$ 22.86
eli lilly glp-1 drugs Gets Speedy FDA Nod for Oral Drug, a Competitor to New Novo Nordisk Pill Eli Lilly slashes prices of
Description
It does not have long-term safety data

Additionally, intraperitoneal administration of GLP-1 at supraphysiological doses elicited an anti-adipogenic effect in rats (72), making GLP-1 a potential target for obesity treatment

What medical comorbidities are associated with NAFLD

The crystal structures of un-acylated liraglutide and semaglutide are almost identical to GLP-1 (37)

Details of the work were published in 2014

For Novo Nordisk, Wegovy holds 16.5% of the market, Rybelsus 6.0% , Saxenda 1.6% , and Victoza 1.1%
